Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Neuroscience

• Publication date

  1986-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/0306-4522(86)90102-8PMID 3489906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey.

  1986cited by this paper
• Reversible parkinsonism related to meperidine.

  1985cited by this paper
• Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

  1985cited by this paper
• The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.

  1985cited by this paper
• Changes in reaction time after pallidal or nigral lesion in the monkey.

  1984cited by this paper
• Parkinson's disease: studies with an animal model.

  1984cited by this paper
• A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man

  1984cited by this paper
• A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics.

  1983cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Motor impairment after unilateral electrolytic lesions of the substantia nigra in baboons: behavioral data with quantitative and kinematic analysis of a pointing movement.

  1983cited by this paper
• Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting.

  1983cited by this paper
• Peripheral DA receptor blockade facilitates behavioural recovery from nigrostriatal damage.

  1983cited by this paper
• Recovery of function and basal ganglia [14C]2-deoxyglucose uptake after nigrostriatal injury.

  1983cited by this paper
• Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.

  1983cited by this paper
• Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections.

  1983cited by this paper
• The crossed mesostriatal projection: neurochemistry and developmental response to lesion.

  1983cited by this paper
• Use of liquid chromatography with electrochemistry to measure effects of varying intensities of white light on DOPA accumulation in rat retinas.

  1982cited by this paper
• Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions.

  1981cited by this paper
• Locomotor control in macaque monkeys.

  1981cited by this paper
• Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

  1979cited by this paper
• Regional distribution of dopamine metabolites in human and primate brain.

  1978cited by this paper
• Time course of nigrostriatal degeneration in parkinson's disease

  1976cited by this paper
• Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

  1973cited by this paper
• The effects of lesions in the substantia nigra.

  1966cited by this paper

• Impairment of neuronal activity in the dorsolateral prefrontal cortex occurs early in parkinsonism

  2025cites this paper
• Innovative care protocol successfully rehabilitates non-human primates after MPTP-induced parkinsonism: Preliminary evidence from a restricted cohort of African Green Monkeys (Chlorocebus sabaeus)

  2025cites this paper
• Impairment of Neuronal Activity in the Dorsolateral Prefrontal Cortex Occurs Early in Parkinsonism

  2024cites this paper
• Establishment of a staging model for Parkinson's disease in mice.

  2023cites this paper
• Spontaneous Partial Recovery of Striatal Dopaminergic Uptake Despite Nigral Cell Loss in Asymptomatic MPTP-Lesioned Female Minipigs.

  2022cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Spontaneous Partial Recovery of Striatal Dopaminergic Uptake Despite Nigral Cell Loss in Asymptomatic MPTP-Lesioned Minipigs

  2021cites this paper
• Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.

  2020cites this paper
• Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway

  2020cites this paper
• Reprint of "Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms".

  2018cites this paper
• Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms.

  2018cites this paper
• Enhancement of Striatal Dopaminergic Function Following Autologous Neural Cell Ecosystems (ANCE) Transplantation in a Non-Human Primate Model of Parkinson’s Disease

  2017cites this paper
• Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

  2017cites this paper
• MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes

  2016cites this paper
• Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.

  2016cites this paper
• Chronic and progressive Parkinson's disease MPTP model in adult and aged mice

  2016cites this paper
• Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson’s disease

  2015cites this paper
• Transplantation of autologous neural cell ecosystems as therapy for Parkinson ’ s disease : a preclinical study

  2015cites this paper
• Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson’s disease for long-term stem cell therapy

  2015cites this paper
• Alteration of Daily and Circadian Rhythms following Dopamine Depletion in MPTP Treated Non-Human Primates

  2014cites this paper
• Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.

  2014cites this paper
• Études de la subthalamotomie comme traitement des dyskinésies chez le primate parkinsonien

  2013cites this paper
• Animal models of Parkinson’s disease and related disorders

  2013cites this paper
• Recovery of Neurological Functions in Non-Human Primate Model of Parkinson's Disease by Transplantation of Encapsulated Neonatal Porcine Choroid Plexus Cells

  2013cites this paper
• The food reaching test: a sensitive test of behavioral improvements by deep brain stimulation in MPTP-treated monkey.

  2012cites this paper
• Manganese mixture inhalation is a reliable Parkinson disease model in rats.

  2012cites this paper
• EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP

  2010cites this paper
• Neuronal and Mitochondrial Protection in Chronic Parkinsonism

  2010cites this paper
• The Unilateral Nigral Lesion Induces Dramatic Bilateral Modification on Rat Brain Monoamine Neurochemistry

  2009cites this paper
• The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: the case of Parkinson's disease.

  2009cites this paper
• Neurodegeneration and peroxidases.

  2009cites this paper
• In vivo gene delivery for development of mammalian models for Parkinson's disease.

  2008cites this paper
• Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.

  2008cites this paper
• Non-human Primate Models of Parkinson's Disease and Experimental Therapeutics

  2008cites this paper
• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice

  2008cites this paper
• Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

  2008cites this paper
• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

  2008cites this paper
• A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.

  2007influential citation
• Uptake and decarboxylation of L-3,4-dihydroxyphenylalanine in cultured monkey placenta amniotic epithelial cells.

  2007cites this paper
• Modifications neurochimiques au sein des ganglions de la base et comportements moteurs associés lors d'une stimulation électrique du noyau subthalamique chez le rat hémiparkinsonien ou de la mise en place de la dénervation dopaminergique chez le singe

  2006cites this paper
• Neural Transplantation in the Nonhuman Primate Model of Parkinson’s Disease

  2006cites this paper
• CIBLAGE ASTROCYTAIRE DE L'EXPRESSION DU GDNF PAR DES LENTIVECTEURS POUR UNE THERAPIE GENIQUE DE PROTECTION DE LA MALADIE DE PARKINSON

  2006cites this paper
• Animal Models of Parkinson ’ s Disease and Related Disorders

  2005cites this paper
• Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity

  2005cites this paper
• CHAPTER B2 – MPTP-Induced Nigrostriatal Injury in Nonhuman Primates

  2005cites this paper
• Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

  2005cites this paper
• Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

  2005cites this paper
• Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease

  2005cites this paper
• Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls

  2004cites this paper
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.

  2004cites this paper
• Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

  2004cites this paper
• Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.

  2003cites this paper
• Progressive Neurodegeneration in a New Mouse Model of Parkinson’s Disease

  2002cites this paper
• Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.

  2002cites this paper
• Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys.

  2001cites this paper
• Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.

  2001cites this paper
• D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.

  2000cites this paper
• The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies.

  2000cites this paper
• Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease.

  1999cites this paper
• Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets

  1999cites this paper
• Experimental models of Parkinson's disease: insights from many models.

  1999cites this paper
• Synthesis and release of catecholamines by cultured monkey amniotic epithelial cells

  1998cites this paper
• Experimental Models of Parkinson's Disease: From the Static to the Dynamic

  1998cites this paper
• MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.

  1998cites this paper
• Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.

  1998cites this paper
• The Use of Neurotoxins to Lesion Catecholamine-Containing Neurons to Model Clinical Disorders

  1998cites this paper
• A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

  1997cites this paper
• Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).

  1997cites this paper
• Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP‐treated common marmoset

  1996cites this paper
• Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.

  1996cites this paper
• Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys.

  1995cites this paper
• Long-term cognitive impairment in MPTP-treated Rhesus monkeys

  1995cites this paper
• Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism

  1995cites this paper
• Quantitative behavioral study of the acute and long-term effects of two-stage bilateral 6-OHDA-induced lesions of the nigrostriatal dopaminergic system in monkeys

  1995cites this paper
• Quantitative behavioral study of the acute and long-term effects of two-stage bilateral 6-OHDA-induced lesions of the nigrostriatal dopaminergic system in monkeys.

  1995cites this paper
• L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.

  1995cites this paper
• Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.

  1995cites this paper
• Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism.

  1995cites this paper
• Sham Surgery does not Ameliorate MPTP-Induced Behavioral Deficits in Monkeys

  1995cites this paper
• Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.

  1995cites this paper
• Behavioral Effects of MPTP Administration in the Vervet Monkey

  1994cites this paper
• Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys.

  1994cites this paper
• Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway.

  1994cites this paper
• Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease.

  1994cites this paper
• Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.

  1994cites this paper
• Recovery from MPTP-Induced Parkinsonism in Monkeys and Cats: Similar Mechanisms?

  1994cites this paper
• Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.

  1993cites this paper
• Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.

  1993cites this paper
• Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study

  1993cites this paper
• Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.

  1993cites this paper
• Developing a stable bilateral model of parkinsonism in rhesus monkeys.

  1993cites this paper
• Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic, and recovered MPTP-treated cats

  1993cites this paper
• Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF.

  1992cites this paper
• Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: the symptomatic versus the asymptomatic condition.

  1992cites this paper
• Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.

  1992cites this paper
• Chronic administration of MPTP to monkeys: behavioural morphological and biochemical correlates.

  1992cites this paper
• Behavioural analysis of unilateral monoamine depletion in the marmoset.

  1992cites this paper
• Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys.

  1992cites this paper
• Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1992cites this paper
• Neurotoxin‐Related Research: From the Laboratory to the Clinic

  1992cites this paper